Israel Englander’s PTC Therapeutics PTCT Stock Holding History

Israel Englander’s Portfolio PTCT Stock Details PTCT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-30,000	Closed	-$1.45M	–	6576
2023 Q1	$1.45M	Buy	+30,000	New	+$1.37M	﹤0.01%	3742
2022 Q3	–	Sell	-10,000	Closed	-$401K	–	7407
2022 Q2	$401K	Buy	+10,000	New	+$351K	﹤0.01%	5128
2016 Q1	–	Sell	-50,000	Closed	-$1.62M	–	3585
2015 Q4	$1.62M	Sell	50,000 -200,000	-80%	-$5.89M	﹤0.01%	2060
2015 Q3	$6.67M	Buy	250,000 +190,000	+317%	+$8.13M	0.01%	1168
2015 Q2	$2.89M	Buy	60,000 +10,000	+20%	+$583K	0.01%	1706
2015 Q1	$3.04M	Buy	+50,000	New	+$3.05M	0.01%	1690

Other funds holding PTCT

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return

Jupiter Topco New York $245B AUM

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Toronto Dominion Bank Toronto, Ontario, Ontario, Canada $86.4B AUM 59.51% 1-Year Est. Return

Westfield Capital Management Boston, Massachusetts $30.6B AUM 61.81% 1-Year Est. Return

Israel Englander's PTCT Position: Q2 2026 in Review

Israel Englander opened a new position in PTC Therapeutics (PTCT) in Q2 2026: 46,494 shares worth $3.79M. The stake represents ﹤0.01% of the portfolio and ranks #3259 among its holdings. This is a return to the name: Israel Englander previously reported a position in PTCT as recently as Q4 2025.

Israel Englander first reported a position in PTCT in Q2 2014 and has held it in 40 quarters since. The position peaked at $64.8M in Q3 2025. 380 funds tracked by Wall St. Rank hold PTCT as of Q2 2026.

Israel Englander held 46,494 shares of PTC Therapeutics worth $3.79M as of Q2 2026.
PTC Therapeutics was a new Israel Englander position in Q2 2026.
PTC Therapeutics made up ﹤0.01% of Israel Englander's portfolio in Q2 2026, its #3259 holding.
Israel Englander first reported a position in PTC Therapeutics in Q2 2014 and has held it in 40 quarters since.
Israel Englander's PTC Therapeutics position peaked at $64.8M in Q3 2025.
380 funds tracked by Wall St. Rank held PTC Therapeutics as of Q2 2026.

Based on Millennium Management's 13F filing for Q2 2026, filed 14 Aug 2026.